Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Disc Medicine, Inc. (NASDAQ:IRON)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired 6,391 shares of Disc Medicine, Inc. (NASDAQ:IRON), valued at approximately $317,000, marking a new investment during the first quarter.
• Several institutional investors notably increased their stakes in Disc Medicine, including FMR LLC, which boosted its holdings by 358.7% during the fourth quarter, now owning over $118 million worth of shares.
• Disc Medicine's recent analyst ratings indicate strong optimism, with an average rating of "Buy" and a price target of $95.73, supported by eleven analysts rating the stock positively.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 6,391 shares of the company's stock, valued at approximately $317,000.

Other hedge funds have also made changes to their positions in the company. Sterling Capital Management LLC increased its stake in Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after purchasing an additional 503 shares during the last quarter. Amalgamated Bank lifted its position in Disc Medicine by 38.6% in the first quarter. Amalgamated Bank now owns 787 shares of the company's stock valued at $39,000 after acquiring an additional 219 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Disc Medicine in the fourth quarter valued at $40,000. Tower Research Capital LLC TRC grew its holdings in shares of Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after purchasing an additional 266 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Disc Medicine during the fourth quarter worth about $235,000. Hedge funds and other institutional investors own 83.70% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Raymond James Financial assumed coverage on Disc Medicine in a research report on Wednesday, June 11th. They set a "strong-buy" rating and a $89.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $118.00 target price on shares of Disc Medicine in a report on Thursday, July 3rd. Morgan Stanley began coverage on shares of Disc Medicine in a research note on Thursday, July 3rd. They set an "overweight" rating and a $85.00 price target for the company. Wedbush restated an "outperform" rating and issued a $90.00 price objective on shares of Disc Medicine in a research note on Monday, July 21st. Finally, Truist Financial initiated coverage on shares of Disc Medicine in a research note on Monday, July 21st. They set a "buy" rating and a $86.00 target price for the company. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $95.73.

Insider Activity

In related news, insider William Jacob Savage sold 2,996 shares of the stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $50.00, for a total transaction of $149,800.00. Following the transaction, the insider directly owned 56,725 shares in the company, valued at approximately $2,836,250. This represents a 5.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Jean M. Franchi sold 2,031 shares of the stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $59.00, for a total transaction of $119,829.00. Following the transaction, the chief financial officer directly owned 63,499 shares in the company, valued at approximately $3,746,441. This represents a 3.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 107,730 shares of company stock valued at $6,210,551 over the last quarter. Insiders own 4.24% of the company's stock.

Disc Medicine Price Performance

NASDAQ IRON traded down $1.83 during mid-day trading on Wednesday, hitting $59.00. The stock had a trading volume of 407,269 shares, compared to its average volume of 366,477. The company has a debt-to-equity ratio of 0.04, a quick ratio of 37.65 and a current ratio of 37.65. Disc Medicine, Inc. has a 52-week low of $30.82 and a 52-week high of $68.73. The company has a 50 day simple moving average of $54.30 and a 200 day simple moving average of $51.42.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.03). On average, equities research analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.